Spaart chemokuur Picoplatin de zenuwen?

In november 2009 werd het nieuwe antikankermiddel Picoplatin aangekondigd. Dit is een platinazout, de kans op neuropathie minder maakt dan de geldende platica zouten.

39353651-Abhijith-Ar-Dreamstime-INP-Instituut-voor-Neuropathische-Pijn picoplatin chemokuurIn een studie met als titel:

  • Randomized Phase 2 study of Picoplatin in Combination with 5-fluorouraciland Leucovorin (FOLPI) as a Neuropathy-Sparing Alternative to mFOLFOX-6as First-line Therapy for Colorectal Cancer (CRC), werd dit gevonden.

Het gaat om resultaten van een fase II-studie. De kans dat dit er bij een fase III-studie ook nog zo positief uitkomt, is zeker niet 100%. We zullen dat eerst moeten afwachten. Wel zijn er al meer dan 1000 patiënten met deze stof behandeld.

Persbericht

In de press release werd de volgende informatie over deze stof en de farmaceutische industrie die het maakt gegeven:

  • SOUTH SAN FRANCISCO, Calif., Nov. 10 /PRNewswire-FirstCall/ — Poniard Pharmaceuticals, Inc. (Nasdaq: PARD) today announced that the Company will present updated clinical data from its randomized, controlled Phase 2 trial of picoplatin in patients with metastatic colorectal cancer (CRC). And final results from its Phase 1 cardiac safety trial. The data from both trials will be presented at a poster session during the AACR-NCI-EORTC’s “Molecular Targets and Cancer Therapeutics” International Conference in Boston. Picoplatin is a new generation platinum-based chemotherapy agent and the Company’s lead product candidate. 

About Picoplatin

  • Picoplatin is a new and differentiated platinum-based chemotherapeutic agent that is in clinical development for multiple cancer indications, treatment combinations and by two routes of administration. It is designed to overcome platinum resistance associated with chemotherapy in solid tumors. Study data to date suggest that picoplatin has an improved safety profile relative to existing platinum-based cancer therapies.
    More than 1,100 patients have received picoplatin. Results obtained to date suggest that hematologic events are common but manageable. Kidney toxicity (nephrotoxicity) and nerve toxicity (neurotoxicity) are less frequent and less severe than is commonly observed with other platinum chemotherapy drugs. Picoplatin has demonstrated anti-tumor activity in a variety of solid tumors

  • In addition to the Phase 1 cardiac safety assessment and the Phase 2 trial in patients with colorectal cancer, Poniard is evaluating intravenous picoplatin in the pivotal Phase 3 SPEAR trial in patients with small cell lung cancer. And in a Phase 2 clinical trial in patients with castration-resistant prostate cancer. Oral picoplatin is being evaluated in a Phase 1 clinical trial in solid tumors.
    Poniard has received both Orphan Drug designation and Fast Track designation for picoplatin for the second-line treatment of refractory or resistant SCLC from the FDA and orphan medicinal product designation for the treatment of SCLC by the European Commission.

Minder polyneuropathie?

De CEO merkte begin 2010 over de doelen van dit middel op: 

  • “We believe that current data from approximately 1,100 patients treated with picoplatin, including data from Phase 2 trials of picoplatin in colorectal, prostate and ovarian cancers, indicate that picoplatin would be a valuable addition to potential partners with marketed and development stage oncology products. We expect to submit efficacy and safety data from the Phase 3 SPEAR trial for potential presentation at the American Society of Clinical Oncology 2010 Annual Meeting in June.”

Dit nieuwe middel zou makkelijker dat cisplatin gecombineerd kunnen worden in chemokuren en zou minder polyneuropathie veroorzaken. Ook de giftigheid voor de nieren zou minder kunnen zijn. We zullen fase III moeten afwachten. 

Bron

Poniard Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative oncology products to impact the lives of people with cancer.

Auteur: Prof. dr. Jan M. Keppel Hesselink, arts-farmacoloog. November 2009

Opioïden voor neuropathische pijn bij chemokuur?

Bekijk hier video’s van onze patiënten over kanker.

Oxaliplatin: verlamming en polyneuropathie
Flupirtine CNSB015 voor neuropathische pijn
ADL5859, een delta agonist voor neuropathische pijn


Mail ons voor het maken van een afspraak

Mail ons voor het maken van een afspraak

Ik ga akkoord met de privacyverklaring*